#USA #New York #Microtech #Medinol #Atrial Microsensor

Microtech Achieves Milestone with First Atrial Microsensor Implantations

Microtech, a wholly owned subsidiary of Medinol, has made a landmark advancement in cardiac technology by successfully conducting the first atrial microsensor implantations in the United States. This groundbreaking procedure took place at New York-Presbyterian/Columbia University Irving Medical Center and was performed by Dr. Koji Takeda on May 16, 2025.

What is the Atrial Microsensor?

The atrial microsensor developed by Microtech is a revolutionary device that showcases an incredibly compact design, is entirely passive, and operates without any electronic components or antennas. Utilizing ultrasound technology, these microsensors can both transmit and receive signals, enabling a new level of non-invasive monitoring in cardiac patients. Importantly, the microsensors can function independently or integrate seamlessly into existing implants, transforming them into advanced, multifunctional diagnostic and therapeutic devices.

Procedure Overview

During the recent implantation procedure at New York-Presbyterian, two microsensors were placed into patients who had undergone Left Ventricular Assist Device (LVAD) implantations. These new sensors join five others that have already been introduced successfully in similar clinical conditions in Israel. Dr. Takeda highlighted the simplicity of the procedure, noting that the microsensor implantation only took about five minutes and required minimal alterations to the established LVAD implantation method.

Benefits of Micropower Technology

The introduction of these microsensors is set to revolutionize the way medical professionals monitor right and left atrial pressures in patients over time. Dr. Nir Uriel, the director of the Advanced Heart Failure and Heart Transplantation Department at NewYork-Presbyterian and the lead investigator of the Microtech First In Human (FIH) study, emphasized how this technology will significantly enhance patient care. Switching from symptom-based treatment to one that is parameter-driven can lead to improved outcomes for patients with severe heart conditions.

In his words, "We have been able to measure these pressures easily, repeatedly, and accurately in all patients who participated in the study so far." Moreover, Dr. Uriel holds prestigious academic positions at Weill Cornell Medicine and Columbia University, underscoring the significance of this study in the medical community.

The Microtech FIH Study

Looking into the future, the Microtech FIH study aims to include around 15 patients across both Israel and the United States, according to Dr. Yoram Richter, CEO of Medinol. The ongoing study showcases promising results regarding the performance and feasibility of the atrial microsensor. Dr. Richter expressed optimism about continuing these advancements, stating that proving the utility and accuracy of this sensor system could lead to widespread clinical adoption.

Additionally, Medinol is actively working on integrating these microsensors into current medical devices, fulfilling the true potential of this innovative technology. As they continue to break new ground in diagnostic and therapeutic applications, Medinol is poised to reshape paradigms in the healthcare industry.

About Medinol

Medinol is committed to transforming the landscape of diagnostic and treatment modalities for various health conditions. Their pioneering efforts range from advanced stenting devices to the development of implantable sensors that provide real-time insights into human physiological parameters. With a forward-thinking approach, Medinol aims to broaden both the physical and geographical reach of healthcare professionals. By collaborating with medical partners, Medinol is not only creating effective solutions today but is also pioneering a promising future for medical technology.

To learn more about Medinol's advancements, visit www.medinol.com or contact Jeff Roache, Chief Commercial Officer, at [email protected]